Présentation Enseignement Recherche Contacts
nos valeurs Microcsb
AFRICASEPTIC : How Africa Will Manage its Own Healthcare

Africaseptic sarl est une nouvelle initiative africaine qui a pour objectif de combler le deficit en Vaccins et produits biologiques

Africaseptic : Comment l’Afrique doit prendre en charge les problemes de santé par la production de vaccins et produits biologiques

CONCEPT For long, Africa has been dependant on vaccination programs initiated by health organizations, both public (WHO, Unicef,…) or private initiatives (Gavi,…). This approach has led to the installation of a “dependency-type” mode for vaccination program, leading often to a lack of efficient vaccination for large populations due to stock-out or other manufacturing issues. The same constraints are observed with some critical medicines such as injectable antibiotics which are mainly supplied from Western countries. To secure the supply of critical drugs and vaccines, Africaseptic is willing to establish in Africa a manufacturing site for injectable products. The classical aseptic filling of injectable drugs in glass vials is probably one of the most difficult processes in the pharmaceutical manufacturing as any contamination is creating a serious risk for the patient with as consequence a septic shock and often patient death. A new opportunity to turn the Africaseptic concept in a reality emerged with the apparition of a new technology developed by Aseptic Technologies, a subsidiary of the leading pharmaceutical company Glaxo SmithKline. This technology, called the Crystal closed vial, is based on the concept that vials are produced in clean environment and immediately closed, leading to clean and sterile vials being ready-to-fill. The use of such ready-to-fill vials leads to several key advantages : • A better quality for the patient as the risk of contamination is strongly reduced if not eliminated. As a demonstration, filling of culture media inside a workshop has shown the absence of contamination despite that the environment was full of potential contaminants • A simplified manufacturing process with much less steps and in particular the elimination of the most difficult ones for glass vials (washing, sterilization, stoppering and capping) • A strong reduction of investment (factories are simple and small without large needs of utilities such as water for washing,…) • A strong reduction of operating costs (no utilities, less validation work, higher productivity,…) • A better supply chain (unbreakable vials,…) and an easier use for healthcare professionals (easy to pierce, easy to collect the liquid,…)

The approach Africaseptic is willing to install two filling lines in Dakar, Senegal with a capacity of 9,000 and 18,000 vials per hour. This means that the company will be able to produce up to 60 Mio vials each year once running full capacity. Africaseptic has already identified several products to be filled on the equipment. In particular, there is currently a lack of yellow fever vaccines and of injectable antibiotics such as Augmentin in West Africa. Africaseptic will purchase bulk products from major pharmaceutical companies and will dispense them in vials locally. By using a local production, the healthcare providers will have a better flexibility and will therefore ensure a better supply to meet the demand of countries in West Africa. Africaseptic will also set up, country by country, a supply chain to deliver the filled vials in the countries of the CEDEAO (16 countries in West Africa). The main clients are expected to be the global organizations such as WHO, Unicef, Gavi,… but also local governments which wants to initiate healthcare initiatives in their countries for the benefit of their fellow citizens. The key advantages for Africa The major advantage of this project is that the drug supply in Africa will be improved, allowing to have better healthcare programs managed locally. Other advantages are coming next to this one : • Easier management of vaccination programs by African Health Ministries • Creation of new high tech employments in Africa • Transfer of technology from Europe to Africa • Reduction of supply costs by using bulk locally The team The company management is made of : • Professor Cheikh Boye : CEO, Professor Boye spent more than 10 years at an International vaccines and drugs Research Group • Dr. Ousmane Sané : COO, Dr. Sané has more than35 years of activity in industry and was founder and General manager of an important Senegalese bicycles company

PDF - 2.4 Mo
PDF - 83.1 ko
PDF - 407.3 ko
Business plan
Africaseptic est une nouvelle société pharmaceutique qui a pour objectif de combler les vaccins et d'autres produits injectables à approvisionner principalement le marché CEDEAO. Savoir plus
Ultimately, the most expensive method of therapy, costing more than surgery or radioiodine Savoir plus
ANDI, group of African health expats and innovators elects co-chairpersons Savoir plus 2011 . Tous droits résérvés   Conception: BiramPouy